US 2022/0033405 A1 · PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT

Abstract

The present invention relates to a pharmaceutical composition for preventing, treating or alleviating cancer, containing a PLK1 inhibitor as an active ingredient, and a compound according to the present invention selectively binds to PBD of PLK1, thereby having advantages of high selectivity and binding affinity for PLK1 and low toxicity. Therefore, a PLK inhibitor compound according to the present invention can be effectively used as an anticancer agent by inhibiting the growth of various cancer cells, and can be expected to exhibit synergistic effects with existing developed anticancer agents through co-administration, in addition to individual administration thereof.

Claims11

Dependent claims

A method of treating cancer, comprising:

administering a compound represented by the following Chemical Formula 1 or 2, or a pharmaceutically acceptable salt thereof, into an individual.
wherein in Chemical Formula 1 or 2,
R1 is H, an alkyl, or —CnH2nCOOH, where n is an integer from 1 to 4,
R2 is H, an alkyl, —CmH2mCN, —CmH2mOR5, —CpH2p(CH(OH))qR6, R5 is a phenyl substituted with one or more C1-3 alkyls, R6 is H, an alkyl, or —OPH2O3, m is an integer from 2 to 4, p is an integer from 1 to 3, and q is an integer from 2 to 4,
R3 is H, a halogen, —NH2, an alkyl, or —CH═O, and
R4 H, an alkyl, —COOH, or —CX3, and X is a halogen.

3 more elements

A health functional food composition for alleviating cancer, comprising a compound represented by the following Chemical Formula 1 or 2, or a pharmaceutically acceptable salt thereof as an active ingredient.

in Chemical Formula 1 or 2,
R1 is H, an alkyl, or —CFnH2nCOOH, where n is an integer from 1 to 4,
R2 is H, an alkyl, —CmH2mCN, —CmH2mOR5, or —CpH2p(CH(OH))qR6, R5 is a phenyl substituted with one or mote C1-3 alkyls, R6 is H, an alkyl, or —OPH2O3, m is an integer from 2 to 4, p is an integer from 1 to 3, and q is an integer from 2 to 4,
R3 is H, a halogen, —NH2, an alkyl, or —CH═O, and
R4 is H, an alkyl, —COOH, or —CX3, and X is a halogen.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/297,852Filed 29 Nov 2018

Priority

KR 10-2018-014911228 Nov 2018

Published

3 Feb 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A23L 33/10
Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof: using additives
A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61P 35/00
Antineoplastic agents

Pharmaceutical composition for preventing or treating cancer containing plk1 inhibitor as active ingredient

Life of this patent

Pharmaceutical composition for preventing or treating cancer containing plk1 inhibitor as active ingredient

Life of this patent

Abstract

Claims11